Ghost Tree Capital, LLC - Q1 2018 holdings

$494 Million is the total value of Ghost Tree Capital, LLC's 53 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was - .

 Value Shares↓ Weighting
INCY NewINCYTE CORPput$83,330,0008,333
+100.0%
16.86%
ECYT NewENDOCYTE INC$19,998,0002,200,000
+100.0%
4.05%
SRPT NewSAREPTA THERAPEUTICS INC$17,411,000235,000
+100.0%
3.52%
IOVA NewIOVANCE BIOTHERAPEUTICS INC$16,900,0001,000,000
+100.0%
3.42%
RCKT NewROCKET PHARMACEUTICALS INC$15,938,000850,000
+100.0%
3.22%
CBIO NewCATALYST BIOSCIENCES INC$11,610,000450,000
+100.0%
2.35%
FOLD NewAMICUS THERAPEUTICS INC$11,280,000750,000
+100.0%
2.28%
MNTA NewMOMENTA PHARMACEUTICALS INC$9,075,000500,000
+100.0%
1.84%
ACAD NewACADIA PHARMACEUTICALS INC$8,988,000400,000
+100.0%
1.82%
CNCE NewCONCERT PHARMACEUTICALS INC$8,015,000350,000
+100.0%
1.62%
ADMS NewADAMAS PHARMACEUTICALS INC$7,766,000325,000
+100.0%
1.57%
ASMB NewASSEMBLY BIOSCIENCES INC$7,371,000150,000
+100.0%
1.49%
RTRX NewRETROPHIN INC$7,029,000314,367
+100.0%
1.42%
AVDL NewAVADEL PHARMACEUTICALS PLCsponsored adr$6,197,000850,000
+100.0%
1.25%
ARWR NewARROWHEAD PHARMACEUTICALS IN$5,768,000800,000
+100.0%
1.17%
GTHX NewG1 THERAPEUTICS INC$5,558,000150,000
+100.0%
1.12%
PTCT NewPTC THERAPEUTICS INC$5,412,000200,000
+100.0%
1.10%
ADRO NewADURO BIOTECH INC$4,650,000500,000
+100.0%
0.94%
FXF NewCURRENCYSHARES SWISS FRANC Tswiss franc sh$4,507,00045,800
+100.0%
0.91%
MRSN NewMERSANA THERAPEUTICS INC$4,388,000278,244
+100.0%
0.89%
TGTX NewTG THERAPEUTICS INC$4,260,000300,000
+100.0%
0.86%
GLYC NewGLYCOMIMETICS INC$4,058,000250,000
+100.0%
0.82%
LCI NewLANNET INC$4,013,000250,000
+100.0%
0.81%
INFI NewINFINITY PHARMACEUTICALS INC$3,675,0001,750,000
+100.0%
0.74%
TSRO NewTESARO INC$3,537,00061,900
+100.0%
0.72%
SLDB NewSOLID BIOSCIENCES INC$2,888,000385,000
+100.0%
0.58%
JNCE NewJOUNCE THERAPEUTICS INC$2,796,000125,092
+100.0%
0.57%
BHVN NewBIOHAVEN PHARMACTL HLDG CO Lcall$1,935,00075,100
+100.0%
0.39%
KPTI NewKARYOPHARM THERAPEUTICS INC$1,030,00076,786
+100.0%
0.21%
ANAB NewANAPTYSBIO INC$937,0009,000
+100.0%
0.19%
MOTS NewMOTUS GI HLDGS INC$448,000100,000
+100.0%
0.09%
IMGN NewIMMUNOGEN INC$225,0007,500
+100.0%
0.05%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MIRATI THERAPEUTICS INC30Q3 20237.3%
ASCENDIS PHARMA A/S - ADR28Q3 202311.8%
BIOCRYST PHARMACEUTICALS INC25Q2 20232.4%
AMICUS THERAPEUTICS INC23Q3 20235.6%
SAREPTA THERAPEUTICS INC22Q3 20239.1%
SPDR SER TR20Q3 202216.9%
IOVANCE BIOTHERAPEUTICS INC18Q2 20235.5%
ROCKET PHARMACEUTICALS INC18Q2 20236.1%
SAGE THERAPEUTICS INC18Q1 20214.8%
IMMUNOMEDICS INC17Q2 20208.7%

View Ghost Tree Capital, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-16

View Ghost Tree Capital, LLC's complete filings history.

Compare quarters

Export Ghost Tree Capital, LLC's holdings